ZIM
KIN

Zacks Investment Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Zacks Investment Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-23,795
Closed -$187K – 673
2017
Q3 		$187K Sell
23,795
-22
-0.1% -$165 ﹤0.01% 532
2017
Q2 		$205K Buy
+23,817
New +$171K 0.01% 536

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PVAM
Pacific View Asset Management San Francisco, California $20.8M AUM 20.08% 1-Year Est. Return

Zacks Investment Management's KIN Position: Q4 2017 in Review

Zacks Investment Management sold out of Kindred Biosciences, Inc. (KIN) in Q4 2017, closing a stake of 23,795 shares — an estimated $187K sold.

Zacks Investment Management first reported a position in KIN in Q2 2017 and held it in 2 quarters. The position peaked at $205K in Q2 2017. 61 funds tracked by Wall St. Rank hold KIN as of Q4 2017.

  • Zacks Investment Management reported no remaining Kindred Biosciences, Inc. position as of Q4 2017 after selling out during the quarter.
  • Zacks Investment Management sold 23,795 Kindred Biosciences, Inc. shares in Q4 2017, an estimated $187K.
  • Zacks Investment Management first reported a position in Kindred Biosciences, Inc. in Q2 2017 and held it in 2 quarters.
  • Zacks Investment Management's Kindred Biosciences, Inc. position peaked at $205K in Q2 2017.
  • 61 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2017.

Based on Zacks Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.